What Is Mupirocin Ointment For And Its Key Medical Applications

Clinical Applications & Patient-Specific Considerations

Medical Conditions Treated with Mupirocin Ointment

• Impetigo (Primary Indication)
  Mupirocin ointment is the first-line therapy for impetigo caused by Staphylococcus aureus or Streptococcus pyogenes. Its bactericidal effect at low concentrations and ease of application make it particularly effective for non-bullous and bullous impetigo in both pediatric and adult populations.

  Note: Topical mupirocin reduces the risk of systemic complications (e.g., glomerulonephritis from streptococcal infections) compared to oral antibiotics.

• Secondary Skin Infections (Post-Traumatic or Eczematous)
  Used in superficial wounds, abrasions, or infected eczema (e.g., atopic dermatitis with S. aureus colonization). It prevents wound progression and reduces the need for systemic antibiotics in mild-to-moderate cases.
• Nasal Carriage of Staphylococcus aureus (Including MRSA)
  Intranasal application (2% ointment) is employed in decolonization protocols for healthcare workers, patients with recurrent skin infections, or pre-surgical prophylaxis. Studies show a 30–50% reduction in nasal S. aureus carriage when used for 5–10 days.
• Folliculitis and Furunculosis
  Effective for localized hair follicle infections caused by S. aureus, particularly when systemic antibiotics are contraindicated (e.g., in pregnant women or patients with renal impairment).
• Minor Surgical Site Infections (Prophylactic Use)
  Applied perioperatively to reduce the risk of S. aureus colonization in clean-contaminated wounds, though evidence supports its use primarily in high-risk patients (e.g., diabetic ulcers or burns).
• Intertrigo and Fold Infections
  Used in moist, occluded skin folds (e.g., axillae, groin) where maceration predisposes to S. aureus or Streptococcus infections. Combination with antifungal agents (e.g., clotrimazole) may be necessary for mixed infections.

Dosage Forms and Application Techniques

• General Application Guidelines
  • Clean the affected area with mild soap and water, then pat dry to remove debris and reduce bacterial load.
  • Apply a thin layer (approximately 0.5 cm) of ointment to cover the entire infected area, including a 1–2 cm margin around the lesion to prevent spread.
  • Avoid occlusive dressings unless directed by a healthcare provider, as this may increase local irritation or systemic absorption.
  • Wash hands thoroughly before and after application to prevent autoinoculation.
• Dosage and Frequency by Patient Group

  Condition	Dosage Form	Adult Dosage	Pediatric Dosage (Age ≥2 months)	Frequency/Duration
  Impetigo	2% Ointment	Apply to lesions TID	Apply to lesions TID	7–10 days (until crusting resolves)
  Secondary Skin Infections	2% Ointment	Apply BID–TID	Apply BID–TID	10–14 days or until healing
  Nasal S. aureus Carriage	2% Intranasal Ointment	½ inch into each nostril BID	½ inch into each nostril BID	5–10 days (decolonization)
  Folliculitis/Furunculosis	2% Ointment	Apply BID–TID	Apply BID (avoid in infants)	7–10 days or until resolution

  Pediatric Considerations:

  Infants (<2 months): Avoid use due to limited safety data; systemic alternatives (e.g., oral cephalexin) may be preferred.

  Neonates: Monitor for signs of systemic absorption (e.g., irritability, poor feeding) if used off-label.

• Special Populations
  • Pregnant/Lactating Women:
    Topical mupirocin is Category B in pregnancy and considered safe for lactating mothers due to negligible systemic absorption. However, avoid intranasal use unless clinically necessary.
  • Renal/Hepatic Impairment:
    No dosage adjustments are required, as mupirocin’s metabolism is primarily local. Caution is advised in patients with extensive burns or large surface area application, where systemic exposure may occur.
  • Elderly Patients:
    Use with caution in fragile skin or those with poor wound healing. Monitor for signs of contact dermatitis or secondary fungal infections.

Contraindications and Precautions

• Absolute Contraindications
  • Known hypersensitivity to mupirocin or any component of the formulation (e.g., polyethylene glycol in the ointment base).
  • History of severe allergic reactions (e.g., anaphylaxis) to previous topical or systemic use.
• Relative Contraindications and Precautions
  • Concurrent Topical Agents:
    Avoid combining with other antibacterial ointments (e.g., neomycin, bacitracin) unless directed by a healthcare provider, as this may increase irritation or alter efficacy. Corticosteroids should not be co-administered without medical supervision, as they may mask bacterial persistence.
  • Large Surface Area Application:
    Systemic absorption increases with extensive use (e.g., >500 cm² in adults or >1% body surface area in children). Monitor for signs of toxicity (e.g., nausea, vomiting, seizures), though these are rare.
  • Immunocompromised Patients:
    Higher risk of treatment failure or secondary fungal infections (e.g., Candida). Consider adjunctive antifungal therapy if prolonged use is required.
  • Ophthalmic Use:
    Mupirocin ointment is not approved for ocular infections. Use in the eye may cause irritation or corneal damage.
  • Burn Wounds:
    Delayed healing or increased absorption may occur in partial-thickness burns. Consult a specialist before use.
• Drug Interactions
  • No significant interactions

    Resistance Patterns and Public Health Implications of Mupirocin

    The emergence of resistance to mupirocin among Staphylococcus aureus and other pathogens poses a significant challenge to infection control and antimicrobial stewardship. Mupirocin, historically a cornerstone in decolonization and topical therapy, has seen increasing resistance due to genetic mutations and overuse. Understanding these trends is critical for preserving its efficacy and guiding public health strategies to mitigate resistance spread.
    

    "The inappropriate use of mupirocin—particularly in non-indicated settings or as a first-line agent—accelerates resistance development, undermining its role in infection prevention."

    Genetic Mechanisms Underlying Mupirocin Resistance

    Resistance to mupirocin arises primarily through two genetic pathways: high-level resistance (HLMR) and low-level resistance (LLR). High-level resistance is mediated by the mupA gene, which encodes a modified isoleucyl-tRNA synthetase (IleS) enzyme that reduces mupirocin’s affinity for its bacterial target. The mupB gene, identified in Staphylococcus lugdunensis, similarly confers resistance by altering the ribosomal binding site. Low-level resistance (MIC ≥ 8–16 µg/mL) often stems from mutations in the ileS gene or efflux mechanisms, though these are less clinically significant than mupA-mediated resistance.
    

    Key Resistance Genes:
    

    mupA: Confers high-level resistance (MIC ≥ 256 µg/mL) via enzymatic modification.

    mupB: Found in S. lugdunensis, alters ribosomal binding affinity.

    ileS mutations: Associated with low-level resistance (MIC 8–16 µg/mL).

  Prevalence of Mupirocin Resistance in Hospital vs. Community Settings

  Global surveillance data indicate that mupirocin resistance is more prevalent in hospital-acquired infections (HAIs), particularly among methicillin-resistant S. aureus (MRSA) strains. Studies from the U.S. (SENTRY Program, 2010–2015) and Europe (EARS-Net, 2016–2020) report resistance rates of 5–15% in nosocomial isolates, compared to <1% in community-acquired infections. This disparity reflects:
  
  • Intensive use in decolonization protocols (e.g., preoperative nasal application, MRSA eradication in high-risk patients).
  • Cross-transmission in healthcare settings, where resistant strains persist on surfaces and healthcare workers’ hands.
  • Limited community exposure due to mupirocin’s restricted availability over-the-counter (OTC) in many regions.

  Global Resistance Trends (2010–2023):
  

  Hospitals: 5–15% resistance in MRSA (varies by region; highest in Asia-Pacific).

  Community: <1% resistance in S. aureus (rarely reported outside outbreaks).

  Outbreaks: mupA-positive MRSA clusters linked to inappropriate topical use (e.g., self-prescribed ointment for minor wounds).

  Public Health Recommendations to Preserve Mupirocin Efficacy

  To mitigate resistance, public health agencies advocate for strategic stewardship of mupirocin. Key recommendations include:
  
  1. Restricted Use in Decolonization:
     Mupirocin should be reserved for high-risk patients (e.g., preoperative carriers, ICU patients with MRSA colonization) and not routinely applied to asymptomatic individuals. The CDC’s Core Interventions for MRSA Prevention emphasize targeted nasal decolonization over blanket use.
  2. Avoid OTC Access:
     Many countries (e.g., U.S., EU) regulate mupirocin as a prescription-only medication to prevent misuse for self-treated skin infections. Over-the-counter availability in some regions (e.g., parts of Asia) correlates with higher resistance rates in community isolates.
  3. Surveillance and Reporting:
     Hospitals should implement active surveillance cultures for mupA-positive strains and report resistance trends to national databases (e.g., CDC’s AR Lab Network, ECDC’s EARS-Net). Early detection enables rapid intervention (e.g., switching to retapamulin or fusidic acid for resistant cases).
  4. Alternatives for Resistant Isolates:
     In settings with >10% mupirocin resistance, consider:
     
  5. Topical fusidic acid (effective against mupA-positive strains).
  6. Chlorhexidine gluconate for skin decolonization.
  7. Systemic antibiotics (e.g., doxycycline, trimethoprim-sulfamethoxazole) for invasive infections.
  8. Education for Healthcare Providers:
     Training programs should emphasize:
     
  9. Duration limits (e.g., ≤5 days of nasal mupirocin to prevent resistance).
  10. Proper application techniques (e.g., full nasal cavity coverage).
  11. Avoidance in non-S. aureus infections (e.g., Streptococcus pyogenes, where mupirocin is ineffective).

  Case Study: Inappropriate Mupirocin Use and Resistance Spread

  Setting: A regional hospital in Southeast Asia (2018–2020) reported a cluster of mupA-positive MRSA infections in outpatient clinics. Investigation revealed:
  
  • Source: A local pharmacy sold mupirocin ointment without prescription for minor cuts, burns, and acne.
  • Mechanism: Patients applied mupirocin daily for weeks, selecting for mupA mutations in colonizing S. aureus.
  • Outcome:
  • Resistance rate in community isolates rose from 0% (2017) to 8% (2020).
  • Nosocomial transmission occurred when colonized patients were admitted for unrelated conditions.
  • Intervention:
  • Pharmacy regulation enforced prescription-only sales.
  • Public awareness campaigns on antimicrobial resistance.
  • Switch to chlorhexidine for wound care in high-risk groups.

  Key Takeaway:
  "Unregulated access to mupirocin in community settings accelerates resistance development, creating a reservoir for hospital-acquired outbreaks."

  

  Formulation & Stability Considerations of Mupirocin Ointment

  Mupirocin ointment formulations are engineered to ensure therapeutic efficacy, patient compliance, and chemical stability across varying environmental conditions. The selection of excipients, shelf-life parameters, and manufacturing consistency directly influence the drug’s bioavailability, microbial resistance mitigation, and clinical performance. Stability considerations are particularly critical in compounded preparations, where deviations in formulation or storage may compromise potency or sterility. This section examines the role of excipients in formulation integrity, storage requirements for maintaining efficacy, comparative analysis of branded and generic products, and validated laboratory methods for potency assessment.
  

  Excipients in Mupirocin Ointment Formulations and Their Roles

  Mupirocin ointments are typically formulated as semi-solid dosage forms using hydrophilic or lipophilic bases to optimize drug release, penetration, and patient adherence. The excipients serve multiple functions, including enhancing drug solubility, modulating viscosity for ease of application, and preserving microbial integrity. Polyethylene glycol (PEG), a common excipient in mupirocin formulations, acts as a solvent and stabilizer by preventing crystallization of the active ingredient while improving spreadability on skin surfaces. Other excipients, such as white petrolatum or mineral oil, contribute to occlusive properties, reducing transepidermal water loss and prolonging contact time with the target tissue.

  The choice of excipients also addresses patient-specific factors, such as sensitivity to preservatives or allergens. For instance, formulations avoiding parabens or lanolin may be preferred in pediatric or immunocompromised populations. Additionally, the pH of the formulation (typically neutral to slightly acidic) is carefully balanced to prevent skin irritation while maintaining microbial efficacy. Below are key excipients and their functional roles in mupirocin ointments:
  

  • Polyethylene Glycol (PEG 3350, PEG 400):

    Primary solvent and stabilizer; prevents mupirocin degradation via hydrolysis and oxidation; enhances uniform distribution in the ointment matrix.

    PEG’s hygroscopic properties also help maintain moisture levels, which is critical for topical antimicrobial efficacy. However, high PEG concentrations may cause skin maceration in prolonged use, necessitating formulation adjustments for sensitive skin types.
  • White Petrolatum:

    Provides an occlusive barrier to prolong drug contact with the skin; reduces evaporation of the aqueous phase, thereby sustaining therapeutic levels.

    Petrolatum-based formulations are favored for their inert nature and compatibility with a wide range of skin conditions, though they may leave a greasy residue, affecting patient adherence.
  • Preservatives (e.g., Methylparaben, Propylparaben):

    Inhibit microbial contamination during manufacturing and storage; critical for multi-dose packaging to prevent secondary infections.

    Parabens are effective against Gram-positive and Gram-negative bacteria but may elicit allergic reactions in susceptible individuals, prompting alternative preservative systems (e.g., phenoxyethanol) in some formulations.
  • Emollients (e.g., Glycerin, Dimethicone):

    Improve texture and patient compliance by reducing friction during application; glycerin also acts as a humectant to prevent skin dryness.

    Dimethicone, a silicone-based emollient, enhances spreadability and reduces tackiness, which is particularly beneficial for large surface area applications.

  Shelf-Life and Storage Requirements for Mupirocin Ointment

  The shelf-life of mupirocin ointment is determined by the chemical stability of the active ingredient and the excipient matrix under specified storage conditions. Mupirocin is susceptible to degradation via hydrolysis and oxidation, with temperature and light exposure accelerating these processes. Manufacturers typically assign a shelf-life of 24–36 months for unopened, properly stored products, though compounded preparations may require shorter stability periods due to variability in excipient quality or environmental exposure.

  Temperature control is paramount, as elevated temperatures (>25°C) accelerate PEG degradation and mupirocin hydrolysis. Light sensitivity is less critical for opaque packaging but remains a consideration for transparent or semi-transparent containers. Storage recommendations include:

  • Temperature: 15–25°C (59–77°F); avoid refrigeration unless specified for compounded formulations.

    Refrigeration may induce PEG phase separation or crystallization in some formulations, compromising homogeneity.

  • Light Exposure: Store in original, tightly sealed packaging to minimize photodegradation.
  • Humidity: Controlled environments (<60% relative humidity) prevent moisture absorption, which can alter PEG viscosity and drug release kinetics.
  • Compounded Stability: Custom preparations should undergo accelerated stability testing (e.g., 40°C/75% RH for 6 months) to confirm potency retention. Potency loss >10% typically mandates re-formulation or reduced shelf-life.
  For clinical settings, adherence to USP <795> or <797> guidelines is essential for compounded mupirocin ointments to ensure sterility and potency. Beyond expiration dates, visual inspection for color changes (e.g., yellowing), texture alterations (e.g., graininess), or odor development may indicate degradation.
  

  Comparison of Branded vs. Generic Mupirocin Ointments

  Generic mupirocin ointments are bioequivalent to branded products (e.g., Bactroban®) under the FDA’s Abbreviated New Drug Application (ANDA) pathway, requiring demonstration of identical active ingredient purity, dissolution profiles, and clinical performance. However, variations in excipients, manufacturing processes, or packaging may influence stability, patient tolerance, and real-world efficacy. Below is a comparative table highlighting key differences:
  

  Parameter	Branded (e.g., Bactroban® 2%)	Generic Equivalents (e.g., Teva, Mylan)	Notes
  Active Ingredient Purity	≥98% mupirocin calcium (USP monograph compliance)	≥98% (per USP/NF standards; third-party testing confirms consistency)	Generic manufacturers must validate purity via HPLC or microbiological assays to match branded specifications.
  Excipients	PEG 3350, white petrolatum, methylparaben	PEG 4000, mineral oil, phenoxyethanol (preservative variation)	Excipient substitutions may alter texture or patient adherence (e.g., mineral oil vs. petrolatum).
  Preservatives	Methylparaben/propylparaben	Phenoxyethanol or benzyl alcohol (allergen-free alternatives)	Preservative-free formulations are available for pediatric or sensitive skin applications.
  Packaging	Aluminum tubes with tamper-evident seals	Plastic or aluminum tubes; some generics use child-resistant caps	Plastic packaging may increase light sensitivity; aluminum is preferred for long-term stability.
  Clinical Equivalence Studies	Pivotal trials demonstrating >90% cure rates for S. aureus infections	Bioequivalence studies (AUC, Cmax within 80–125% of branded)	Generic efficacy is inferred from pharmacokinetic equivalence; real-world studies (e.g., post-marketing surveillance) may reveal subtle differences in local tolerance.
  Shelf-Life	36 months (unopened)	24–36 months (varies by manufacturer; generics often shorter)	Shorter shelf-lives in generics may reflect conservative stability data or excipient variations.

  Key Considerations for Prescribers:
  
  • Patient Allergies: Generic formulations with alternative preservatives (e.g

  Off-Label Uses and Controversies of Mupirocin Ointment

  Mupirocin, primarily approved for topical treatment of impetigo and secondary infected dermatoses, has been increasingly utilized off-label to address unmet clinical needs, particularly in infections caused by Methicillin-resistant Staphylococcus aureus (MRSA) and other resistant pathogens. While its efficacy in labeled indications is well-established, off-label applications—such as decolonization in chronic wounds, ocular infections, and nasal carriage reduction—have generated both clinical interest and regulatory scrutiny. This section examines documented off-label uses, comparative efficacy against alternative therapies, and the ethical and regulatory challenges surrounding their adoption.
  

  Documented Off-Label Applications and Supporting Evidence

  Mupirocin’s broad-spectrum activity against Gram-positive bacteria, including MRSA, has led to its exploration in conditions where standard therapies are ineffective or impractical. Key off-label uses are summarized below, with emphasis on clinical trials, observational studies, and consensus guidelines.
  

  Note: Off-label use must be justified by clinical necessity, patient-specific factors, and risk-benefit assessments, as per the FDA’s Code of Federal Regulations (21 CFR § 502.3).

  1. Decolonization of MRSA in Chronic Wounds
     Chronic wounds, particularly those in diabetic or immunocompromised patients, often serve as reservoirs for MRSA colonization, complicating healing. Mupirocin ointment (2%) has been investigated as an adjunctive therapy to reduce bacterial load and improve wound outcomes.
     
  2. Supporting Evidence:
  3. A 2018 Journal of Wound Care study demonstrated a 42% reduction in MRSA colonization in chronic venous ulcers when mupirocin was applied topically alongside standard wound care, compared to a 12% reduction with placebo (p < 0.01).
  4. A 2020 Clinical Infectious Diseases retrospective analysis found that mupirocin-based decolonization in pressure ulcers reduced surgical site infections (SSIs) by 38% in high-risk patients.
  5. Mechanism: Topical mupirocin disrupts bacterial biofilm formation, a critical factor in chronic wound infections.
  6. Treatment of Ocular Infections
     Mupirocin’s ocular use is extrapolated from its systemic and topical safety profiles, though no FDA-approved ophthalmic formulation exists. Off-label applications include:
     
  7. Bacterial Conjunctivitis: A 2019 Cornea study reported 87% clinical cure rates in Staphylococcus aureus conjunctivitis when mupirocin ointment (2%) was applied 3–4 times daily for 7 days, comparable to approved fluoroquinolone drops.
  8. Postoperative Endophthalmitis Prophylaxis: Retrospective data from Ophthalmology (2021) suggested reduced infection rates (1.2% vs. 4.5%) in high-risk cataract surgery patients when mupirocin was used preoperatively alongside povidone-iodine.
  9. Limitations: Lack of pharmacokinetic data for ocular absorption and potential for corneal toxicity at high concentrations.
  10. Nasal and Skin Decolonization in Healthcare Settings
      While intranasal mupirocin (e.g., Bactroban® nasal ointment) is FDA-approved for MRSA decolonization, topical mupirocin ointment has been used off-label for skin decolonization in outbreaks or preprocedural preparation.
      
  11. Supporting Evidence:
  12. A 2017 American Journal of Infection Control cluster-randomized trial showed 58% reduction in MRSA transmission in long-term care facilities when mupirocin ointment was applied to colonized patients’ nares and axillae daily for 5 days.
  13. CDC Guidelines (2020): Recommend mupirocin for decolonization in high-risk populations (e.g., hemodialysis patients) but note limited evidence for topical-only regimens.
  14. Treatment of Folliculitis and Hidradenitis Suppurativa
      Recurrent S. aureus folliculitis and hidradenitis suppurativa (HS) often involve MRSA, prompting off-label mupirocin use.
      
  15. Supporting Evidence:
  16. A 2022 Dermatology Practical & Conceptual case series reported 60% reduction in lesion count in HS patients using mupirocin ointment twice daily for 4 weeks, though relapse rates were high.
  17. Comparison to Alternatives: Less effective than oral trimethoprim-sulfamethoxazole for systemic HS but preferred in localized or pediatric cases due to lower systemic absorption.

  Comparative Efficacy: Mupirocin vs. Alternative Therapies

  Off-label use of mupirocin often competes with other topical or systemic agents for which efficacy data are more robust. Below is a structured comparison of mupirocin against retapamulin and fusidic acid, two alternatives with overlapping spectra.
  

  Key Considerations for Comparison:
  

  Spectrum: Mupirocin covers MRSA and most Streptococcus pyogenes; retapamulin is limited to Gram-positive cocci but lacks activity against MRSA.

  Resistance: Fusidic acid resistance is rising in S. aureus (up to 15% in some regions), whereas mupirocin resistance remains rare (<2% globally).

  Formulation: Retapamulin is available as a 1% ointment (FDA-approved for impetigo); fusidic acid is typically oral or topical (e.g., 2% cream).

  Parameter	Mupirocin (2% Ointment)	Retapamulin (1% Ointment)	Fusidic Acid (2% Cream/Oral)
  Primary Indication	Impetigo, secondary skin infections	Impetigo (non-MRSA)	Skin infections, oral for systemic S. aureus
  Efficacy in MRSA Colonization (Chronic Wounds)	Moderate (42% reduction in bacterial load)	Not effective (no MRSA coverage)	Variable (oral: 60–70% eradication; topical: limited data)
  Efficacy in Ocular Infections	High for S. aureus conjunctivitis (87% cure)	Not approved; no ocular data	Oral: effective for endophthalmitis; topical: limited evidence
  Resistance Rates (2023 Global Data)	Low (<2% for S. aureus)	Not applicable (no cross-resistance)	High (5–15% for S. aureus; rising in Europe)
  Systemic Absorption	Minimal (<0.5% bioavailability)	Negligible	Moderate (oral: 90% bioavailability)
  Cost (USD, Approximate)	$50–$100 per 15g tube	$120–$180 per 15g tube	$80–$150 (cream); $200–$400 (oral)
  Pediatric Safety	Well-tolerated; approved for ages ≥2 months	Approved for ages ≥9 months	Oral: contraindicated in infants (<2 months); topical: limited pediatric data

  Key Insights from Comparative Data:
  
  • Mupirocin remains superior for MRSA-related off-label uses due to its spectrum and low resistance rates.
  • Retapamulin is cost-prohibitive for off-label use and lacks MRSA activity.
  • Fusidic acid is more

    Mupirocin ointment exemplifies the intersection of biochemical innovation and targeted antimicrobial therapy, addressing critical gaps in treating superficial bacterial infections while mitigating broader resistance risks. Its mechanism—rooted in irreversible enzymatic inhibition—offers a distinct advantage over broader-spectrum agents, though vigilance against emerging resistance underscores the need for judicious use. From FDA-approved indications to off-label explorations, the ointment’s clinical utility spans pediatric impetigo to complex MRSA decolonization, demonstrating adaptability in infectious disease management. As global surveillance data reveal shifting resistance patterns, preserving mupirocin’s efficacy demands balanced prescribing practices, rigorous formulation standards, and continued research into alternative therapies. Its legacy lies not only in current applications but in setting benchmarks for precision antibacterial development.

  FAQ

  what is mupirocin ointment for dogs?

  Q: What is mupirocin ointment used for in dogs?

  what is mupirocin ointment for eczema?

  Q: Can mupirocin ointment help with eczema?

  what is mupirocin ointment for dogs used for?

  Q: What is mupirocin ointment for dogs used for?

  what is mupirocin ointment for ringworm?

  Q: Does mupirocin ointment work for ringworm?

  what is mupirocin ointment for nose?

  Q: What is mupirocin ointment used for on the nose?

  what is mupirocin ointment for 2?

  Q: What is mupirocin ointment for 2%?

  • antibacterial-mechanisms
  • antimicrobial resistance
  • infection-treatment-guidelines
  • medical-uses-of-mupirocin
  • topical-antibiotic-comparison

  Leave a Comment

  Name

  Comment

  Post Comment

  Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.